An experimental Eli Lilly drug slowed cognitive and functional decline for people with early-stage Alzheimer’s disease in a new study that could support regulatory approval and commercial sale
that was among the first to significantly slow the worsening of the memory-robbing disease, after years of failed attempts by the drug industry to find such drugs.
In the study of more than 1,730 patients, the drug slowed patients’ decline by 35% compared with people who received a placebo over 18 months of treatment, Lilly said. “These are levels of efficacy that just haven’t been seen before in Alzheimer’s, setting a new benchmark for what’s possible in this disease,” Dr. Skovronsky said.
About 1.6% of the abnormalities were classified as serious, including two people who died from them and a third person who died after an abnormality, Lilly said.from a smaller, midstage study in 2021. Based on that study, Lilly applied for approval from the FDA. The agency said it needed more data before it could make a decision.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Eli Lilly's diabetes drug could revolutionize the US weight loss marketEli Lilly’s diabetes drug delivers promising results in a recent clinical trial. The company hopes it will be added to the U.S. weight loss market soon.
Lire la suite »
The Book Of Eli Ending & Meaning ExplainedThe post-apocalyptic action movie The Book of Eli features a surprise twist ending that leaves audiences with a lot of unanswered questions.
Lire la suite »
Man admits he robbed financial services company of more than $1MEli Schamovic, 41, of Lakewood, pleaded guilty to money laundering in U.S. District Court.
Lire la suite »
Your nonacademic career is not a consolation prize“You didn’t lose the gameshow. You just found a different way to win.” ScienceCareers
Lire la suite »
Inside the Secretive Life-Extension ClinicLongevity evangelists are injecting people with experimental gene therapies. There are no guarantees—and no refunds.
Lire la suite »